Studi Evaluasi Efek Samping Penggunaan Vaksin COVID-19 Terhadap Masyarakat Sebatik Timur
Study Evaluating the Side Effects of the Use of the COVID-19 Vaccine on the Eastern Sebatik Community
Keywords:COVID-19, Side Effects, Vaccination
Vaccination is an effective prevention of disease transmission and an obligation to ensure the availability of vaccines, especially during this COVID-19 pandemic where the availability of vaccines has an Emergency Use Approvel (EUA) permit so that further research is needed on the effects. This study aims to see the effect of using the COVID-19 vaccine on people in East Sebatik. The research design used was a prospective non-experimental method with data collection techniques, namely purposive sampling. The subjects of this study were 100 people who were vaccinated against COVID-19 stage 1 and stage 2 in East Sebatik, especially those carried out by the East Sebatik Health Center. The result of this research is that the majority of respondents based on gender characteristics are women as many as 68 respondents (68%). The majority of respondents based on age characteristics are in the adult age group (26-45 years) as many as 54 respondents (54%). The majority of respondents based on the characteristics of the history of the disease were non-complicated as many as 67 respondents (67%). COVID-19 vaccine is currently restricted to age ? 18 years. The majority respondents based on side effect after the COVID-19 vaccine dose 1 was pain in the area of the injection site, which was 39 respondents (39%). And the majority of respondents based on side effect after COVID-19 vaccine dose 2 were 17 respondents (17%).
Li, X., Geng, M., Peng, Y., Meng, L., & Lu, S. (2020). Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal, 10(2), 102-108, https://doi.org/10.1016/j.jpha.2020.03.001
Liu, S., Luo, H., Wang, D., Ju, S., & Yang, Y. (2020). Characteristics and Associations with Severity in COVID-19: a multicentre cohort study from Jiangsu province, China. The Lancet.
Yuliana. 2020. Corona Virus Disease (COVID-19); Sebuah Tinjauan Literatur. Wellness and Healthy Magazine, Volume 2, Nomor 1, p. 187-192. ISSN 2655-9951 (print), ISSN 2656-0062 (online).
https://www.pom.go.id/new/view/more/pers/584/Penerbitan-Persetujuan Penggunaan-Dalam-Kondisi-Darurat-Atau-Emergency-Use-Authorization--EUA--Pertama-Untuk-Vaksin-COVID-19.html (Diakses pada 25 April 2021).
Yuningsih, Rahmi. 2020. Uji Klinik Coronavac dan Rencana Vaksinasi COVID-19 Massal di Indonesia. Pusat Penelitian Badan Keahlian DPR RI, Vol. XII, No. 16/II/Puslit/Agustus/2020.
Kementerian Kesehatan Republik Indonesia. 2020. FAQ Seputar Pelaksanaan Vaksinasi COVID-19. Gerakan Masyarakat Hidup Sehat.
https://www.pom.go.id/new/view/more/berita/20883/Badan-POM-Terbitkan-EUA--Vaksin-CoronaVac-Sinovac-Siap-Disuntikkan.html (Diakses pada 25 April 2021).
Ciarambino T, Barbagelata E, Corbi G, Ambrosino I, Politi C, Lavelle F, Ruggieri A, Moretti A. 2021. Gender Differences in Vaccine Theraphy: Where Are We In COVID-19 Pandemic. Monaldi Archives for Chest Dis. doi: 10.4081/monaldi.2021.1669. Epub ahead of print. PMID: 33840183.
Mazure C. 2021. Sex and Gender and COVID-19 Vaccine Side Effect. http://medicine.yale.edu/news-article/sex-and-gender-and-covid-19-vaccine-side-effcts/ (Accessed: 19 November 2021).
Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, Hu G, Wang Z, Zheng F, Wang L. 2020. A Comparison Study of SARS-CoV-2 IgG Antibody Between Male and Female COVID-19 Patients: A Possible Reason Underlying Different Outcome Between Sex. J Med Virol. Vol 92 (10): 2050-2054.
El-Elimat T., et al. 2021. Acceptence and attitudes toward COVID-19 vaccines: A Cross-Sectional Study from Jordan. PLoS ONE. Vol 16: 1-15.
Lazarus, JV, et al. 2021. A Global Survey of Potential Acceptence of a COVID-19 Vaccine. Nature Meicine. Vol 27 (2): 225-228.
Lidiana, Exda, Hanung, dkk. 2021. Gambaran Karakteristik Kejadian Ikutan Pasca Vaksinasi COVID-19 pada Tenaga Kesehatan Alumni Universitas ‘Aisyiyah Surakarta. Jurnal Ilmiah Kesehatan.
Koesnoe S. (2021). Teknis Pelaksanaan Vaksin Covid dan Antisipasi KIPI. https://www.papdi.or.id/pdfs/1001/Dr%20Sukamto%20-%20Ws%20Vaksin%20Covid%20KIPI.pdf
Rengganis I. (2021). Vaksinasi COVID-19. https://www.papdi.or.id/pdfs/999/Prof%20Iris%20Rengganis%20-%20Vacc%20COVID-19%20Workshop%2018%20Januari%202021.pdf
How to Cite
Copyright (c) 2021 Proceeding of Mulawarman Pharmaceuticals Conferences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.